Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...
New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), ...
The following is a summary of “Global Delphi consensus on treatment goals for generalised pustular psoriasis,” published in the January 2025 issue of Dermatology by Barker et al. Generalized pustular ...
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis <li /> Vanda expects to immediately ...
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
This case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, as well as highlights the unique ...
AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...
Centers for Disease Control and Prevention. Preventing and treating skin infections. National Psoriasis Foundation. Pustular psoriasis. American Academy of Dermatology. Is that eczema or an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback